Assessment of molecular alterations such as CDKN2A/B hemizygous loss may also be dependent on the assays used and tumor purity of samples, though we approached these analyses as representative of real-world sequencing methodologies implemented in clinical practice. The gene discussed is CDKN2A; the disease is neoplasm.